ClinicalTrials.gg
CompletedNCT04916977GROUNDUpdated Nov 28, 2023

Global Burden and Treatment Trajectiories in Italian Patients With Fabry Disease

An observational study in Fabry Disease, sponsored by Chiesi Italia. Completed at 7 sites in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-11-28.

Sponsored by Chiesi Italia (part of Chiesi Farmaceutici S.p.A.) · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
200
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 10 studies in Fabry Disease by Chiesi Farmaceutici S.p.A. — 5 open to participants now, 5 under way, 2 of them phase 3. Fabry Disease · Chiesi Farmaceutici S.p.A..

Started
2021
the only one that year
Observational
5 of 10
3 open now
Registered
4th of 10
by date

Among the 10 studies in Fabry Disease by Chiesi Farmaceutici S.p.A., this one is the only one that started in 2021, is one of 5 observational ones, and was the 4th registered.

Fabry Disease

244 studies on the registry are indexed under Fabry Disease; 54 are open to participants now.

Browse Fabry Disease studies →

Open to participants now

5 of the 10 studies in Fabry Disease by Chiesi Farmaceutici S.p.A. are open now, in 10 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 44 Fabry Disease studies recruiting now, 31 (70%) set no upper age limit and 11 (25%) stop at 75 or younger; 20 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Fabry Disease by Chiesi Farmaceutici S.p.A., or all of them as a file.
02

Study summary

GROUND study is an Italian, multicenter retrospective longitudinal cohort study with a cross-sectional phase with the aim to quantify the severe clinical burden in terms of severe and fatal outcomes and extension of clinical impairment in the Italian Fabry Disease patients' population

03

Conditions studied

  • Fabry Disease

Browse trials for

Keywords

  • Fabry Disease
  • Rare
  • Retrospective
  • Burden
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients with a confirmed FD diagnosis

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adult patients living or deceased of either sex (age ≥18 years) with a documented FD diagnosis in the last 10 years from the beginning of the study.
  2. Patients with at least 3 years of follow-up or early occurrence of severe/fatal outcomes. Also, adult patients who were lost by their care provider or physician and cannot be traced, but for which it is possible to retrieve data for at least 3 years before the last available follow-up visit or from diagnosis to the occurrence of severe/fatal outcomes if earlier, can be included.
  3. Written to undergo in the cross-sectional protocol clinical visit and to retrospectively collect genetic/clinical data. In case of deceased or untraceable patients, the written informed consent is not required to collect retrospective clinical data (excluding genetic data).

Exclusion criteria

Exclusion Criteria:

  • Not applicable
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
200 participants (actual)
Patient registry
No

Groups and cohorts

  • FD patients

    Other: FD patients

Interventions

  • OtherFD patients

    Patients with Fabry disease diagnosis

06

What researchers measure

Primary outcomes

  1. Occurrence of severe and fatal clinical outcomes

    Occurrence of severe and fatal clinical outcomes derived by event-free survival from birth to last follow-up or cross-sectional visit;

    Time frame: Baseline

  2. Comprehensive burden

    Comprehensive burden intended as a measure of extension of clinical impairment assessed by median Mainz Severity Score Index (MSSI) at last follow-up or cross-sectional visit.

    Time frame: Baseline

Secondary outcomes

  1. Percentage of patients with disease progression

    Percentage of patients with disease progression measured by FAbry STabilization indEX and defined as a change \>20% from the first available FASTEX score to the last follow-up and in the last 2 years until the last follow-up and 2 years before the last follow-up or cross-sectional visit (or when available within 3-1 years before last follow-up)

    Time frame: From the first available FASTEX score to baseline

  2. Percentage of patients with disease activity

    Percentage of patients with disease activity assessed by the occurrence rate of clinically significant events from diagnosis to last follow-up or cross-sectional visit.

    Time frame: Baseline

  3. Brief pain inventory score

    Uses simple numeric rating scales from 0 (no pain) to 10 (severe pain)

    Time frame: Baseline

  4. Pittsburgh Sleep Quality index

    Seven component scores are derived, each scored 0 (no difficulty) to 3 (severe difficulty). The component scores are summed to produce a global score (range 0 to 21). Higher scores indicate worse sleep quality.

    Time frame: Baseline

  5. Hamilton depression scale

    It contains 17 items. A score of 0-7 is considered to be normal while a score of 20 or higher (indicating at least moderate severity)

    Time frame: Baseline

  6. HAQ-disability index

    There are 8 sections: dressing, arising, eating, walking, hygiene, reach, grip, and activities. There are 2 or 3 questions for each section. Scoring within each section is from 0 (without any difficulty) to 3 (unable to do).The 8 scores of the 8 sections are summed and divided by 8.

    Time frame: Baseline

  7. SF-36

    Covers eight health domains: physical functioning (10 items), bodily pain (2 items), role limitations due to physical health problems (4 items), role limitations due to personal or emotional problems (4 items), emotional well-being (5 items), social functioning (2 items), energy/fatigue (4 items), and general health perceptions (5 items). Scores for each domain range from 0 to 100, with a higher score defining a more favorable health state.

    Time frame: Baseline

  8. Time from first manifestation to diagnosis

    Time from first manifestation to diagnosis

    Time frame: Baseline

  9. Patients prescribed to different treatments

    Percentage of patients prescribed to different treatment among naïve and switchers groups; determinants of untreated, treated discontinue, treated persisting status.

    Time frame: Baseline

07

Study locations

7 sites
  • AUSL Toscana Sud-Est - Ospedale San Donato
    Arezzo, Italy
  • A.O.U. Careggi
    Firenze, Italy
  • U.O.C. Nefrologia ASST Monza - Ospedale San Gerardo
    Monza, Italy
  • U.O. di Nefrologia - Dipartimento di Sanità Pubblica Università degli Studi di Napoli "Federico II" NAPOLI
    Napoli, Italy
  • A.O.U. Policlinico "Giaccone"
    Palermo, Italy
  • AUSL della Romagna - Ospedale Infermi
    Rimini, Italy
  • Fondazione Policlinico Universitario "Gemelli" IRCCS
    Roma, Italy
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2021 to primary completion in Jun 2022, 12 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 13, 2021
First posted
Jun 8, 2021
StartActual
Jun 23, 2021
Primary completionActual
Jun 30, 2022
CompletionActual
Jun 30, 2022
Last update
Nov 28, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 28, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04916977
Lead sponsor
Chiesi Italia
Responsible party
Sponsor
First posted
Jun 8, 2021
Start date
Jun 23, 2021
Primary completion
Jun 30, 2022
Completion
Jun 30, 2022
Last update
Nov 28, 2023

Study contacts

Antonio Pisani, MD
principal investigator · Università degli Studi di Napoli "Federico II" NAPOLI
Federico Pieruzzi, MD
principal investigator · Ospedale San Gerardo MONZA
Renzo Mignani, MD
principal investigator · AUSL della Romagna - Ospedale Infermi RIMINI
Elena Verrecchia, MD
principal investigator · Fondazione Policlinico Universitario "Gemelli" IRCCS ROMA
Davide Noto, MD
principal investigator · A.O.U. Policlinico "Giaccone" PALERMO
Antonino Tuttolomondo, MD
principal investigator · A.O.U. Policlinico "Giaccone" PALERMO
Maurizio Pieroni, MD
principal investigator · AUSL Toscana Sud-Est - Ospedale San Donato AREZZO
Iacopo Olivotto, MD
principal investigator · A.O.U. Careggi FIRENZE

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion